ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

AHF: Drain the Apexus Swamp

By virtue of its exclusive contract to manage the 340B Drug Pricing Program since 2004, Apexus has become a government-sanctioned entity fraught with self-dealing interests in the 340B marketplace. AIDS Healthcare Foundation (AHF) welcomes Senator Bill Cassidy’s (R-LA) inquiry into Apexus. The prime vendor is a wolf in sheep’s clothing, leveraging its former nonprofit status to procure the federal contract while generating significant revenue for its for-profit parent company, Vizient, the nation’s largest group purchasing organization for prescription drugs.

In theory, the prime vendor negotiates sub-340B ceiling price discounts on behalf of all eligible nonprofit healthcare providers. Unfortunately, AHF has experienced how Apexus negotiates in practice. In 2022, AHF filed suit against Apexus, alleging that the federal contractor failed to negotiate in good faith for sub-ceiling price discounts on HIV therapeutics. Despite its contractual mandate, Apexus directs time and resources toward negotiating the prices of drugs most used by larger 340B hospital clients of Vizient. The AHF complaint also alleges a lack of ethical firewalls, as Apexus makes no effort to separate its prime vendor obligations from other business verticals under the Vizient umbrella.

Apexus was the subject of a scathing 2025 New York Times exposé based on interviews of current and former employees, internal memoranda, and company emails that document how Apexus “supercharges” 340B to benefit its bottom line. According to the report, Apexus has an incentive to increase 340B purchases since it makes a fee for almost every drug sold in the program. More fees for Apexus mean greater profits for Vizient. It makes sense to focus on the large hospital systems responsible for 80% of 340B purchases. That is why Apexus has no business administering the 340B program. The conflict of interest provides cause for the Department of Health and Human Services to void the Apexus contract immediately.

AIDS Healthcare Foundation (AHF), the world’s largest HIV/AIDS healthcare organization, provides cutting-edge medicine and advocacy to more than 2.8 million individuals across 50 countries, including the U.S. and in Africa, Latin America/Caribbean, the Asia/Pacific Region, and Eastern Europe. In January 2025, AHF received the MLK, Jr. Social Justice Award, The King Center’s highest recognition for an organization leading work in the social justice arena. To learn more about AHF, visit us online at AIDShealth.org, find us on Facebook, and follow us on Instagram, Twitter, and TikTok.

Apexus has become a government-sanctioned entity fraught with self-dealing interests in the 340B marketplace. AIDS Healthcare Foundation (AHF) welcomes Senator Bill Cassidy’s (R-LA) inquiry into Apexus. The prime vendor is a wolf in sheep’s clothing.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  242.96
+3.66 (1.53%)
AAPL  270.01
+10.53 (4.06%)
AMD  246.27
+9.54 (4.03%)
BAC  54.03
+0.83 (1.56%)
GOOG  344.90
+6.37 (1.88%)
META  706.41
-10.09 (-1.41%)
MSFT  423.37
-6.92 (-1.61%)
NVDA  185.61
-5.52 (-2.89%)
ORCL  160.06
-4.52 (-2.75%)
TSLA  421.81
-8.60 (-2.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.